ASTH Valuation

Astrana Health Inc

Add to Watchlist

Advanced Chart

23.270

+0.775(3.445%)1D

Overview
Forecast
Valuation
Earnings

ASTH Relative Valuation

ASTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASTH is overvalued; if below, it's undervalued.

Historical Valuation

Astrana Health Inc (ASTH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.21 is considered Undervalued compared with the five-year average of 36.94. The fair price of Astrana Health Inc (ASTH) is between 32.19 to 90.25 according to relative valuation methord. Compared to the current price of 22.81 USD , Astrana Health Inc is Undervalued By 29.14%.

Relative Value

Fair Zone

32.19-90.25

Current Price：22.81

29.14%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.48

P/B

Median3y

2.88

Median5y

3.76

4.64

FCF Yield

Median3y

2.81

Median5y

3.28

Competitors Valuation Multiple

The average P/S ratio for ASTH's competitors is 1.23, providing a benchmark for relative valuation. Astrana Health Inc Corp (ASTH) exhibits a P/S ratio of 0.32, which is -74.16% above the industry average. Given its robust revenue growth of 53.43%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap